Phaseline

Targets › GSN

GSN (Gelsolin): drug programs, companies and trials

2 programs from 1 company in 2 trials: 2 Phase 2; Infectious disease, Other; next expected readout Oct 2027.

Calcium-regulated, actin-modulating protein that binds to the plus (or barbed) ends of actin monomers or filaments, preventing monomer exchange (end-blocking or capping). It can promote the assembly of monomers into filaments (nucleation) as well as sever filaments already formed. (UniProt, P06396)

Open in Phaseline: the race on GSN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
BioAegis TherapeuticsRhu-pGSN
Recombinant human gelsolin - actin-scavenging protein that reduces inflammatory cell damag
GSNPhase 2Acute Respiratory Distress SyndromeOct 2027
BioAegis TherapeuticsRecombinant human plasma gelsolin
Plasma gelsolin acts as a scavenger of actin released from damaged cells and modulates inf
GSNPhase 2Decompression Sickness–

Conditions

Acute Respiratory Distress Syndrome (1) Decompression Sickness (1)

Modalities

small molecule (2)

Companies

BioAegis Therapeutics (2)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.